| Literature DB >> 27877036 |
Cindy Strehl1, Lionel Maurizi2, Timo Gaber1, Paula Hoff1, Thomas Broschard3, A Robin Poole4, Heinrich Hofmann2, Frank Buttgereit1.
Abstract
Combined individually tailored methods for diagnosis and therapy (theragnostics) could be beneficial in destructive diseases, such as rheumatoid arthritis. Nanoparticles are promising candidates for theragnostics due to their excellent biocompatibility. Nanoparticle modifications, such as improved surface coating, are in development to meet various requirements, although safety concerns mean that modified nanoparticles require further review before their use in medical applications is permitted. We have previously demonstrated that iron oxide nanoparticles with amino-polyvinyl alcohol (a-PVA) adsorbed on their surfaces have the unwanted effect of increasing human immune cell cytokine secretion. We hypothesized that this immune response was caused by free-floating PVA. The aim of the present study was to prevent unwanted immune reactions by further surface modification of the a-PVA nanoparticles. After cross-linking of PVA to nanoparticles to produce PVA-grafted nanoparticles, and reduction of their zeta potential, the effects on cell viability and cytokine secretion were analyzed. PVA-grafted nanoparticles still stimulated elevated cytokine secretion from human immune cells; however, this was inhibited after reduction of the zeta potential. In conclusion, covalent cross-linking of PVA to nanoparticles and adjustment of the surface charge rendered them nontoxic to immune cells, nonimmunogenic, and potentially suitable for use as theragnostic agents.Entities:
Keywords: cell viability; cross-linking; cytokine secretion; iron oxide nanoparticles; polyvinyl alcohol; surface charge
Mesh:
Substances:
Year: 2016 PMID: 27877036 PMCID: PMC5110004 DOI: 10.2147/IJN.S110579
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Physicochemical characterization of SPION with adsorbed amino-PVA (a-PVA-SPION) and grafted PVA with amino groups (a-PVA-grafted-SPION)
| Nanoparticles | dcore (nm) | dH (nm) | Z potential (mV) | Sat mag (emu/g) | Conc (mgFe/mL) | PVA/Fe mgPVA/mgFe |
|---|---|---|---|---|---|---|
| Naked SPION | 7.2±2.5 | 14±2 | 1±3 | 54 | 10 | 0 |
| a-PVA-SPION | 7.2±2.5 | 31±10 | 22±6 | 54 | 5 | 9 |
| a-PVA-grafted-SPION (++) | 7.2±2.5 | 28±8 | 31±5 | 54 | 5 | 1 |
| a-PVA-grafted-SPION (+) | 7.2±2.5 | 32±7 | 21±2 | 54 | 5 | 1 |
Abbreviations: dcore, mean diameter of the magnetic core; dH, hydrodynamic diameter of a-PVA-SPION; Z potential, zeta potential; sat mag, saturation magnetization; conc, concentration of SPION; PVA/Fe, chemical mass ratio of PVA to iron; SPION, superparamagnetic iron oxide nanoparticles; PVA, polyvinyl alcohol.
Figure 1Schematic representation of the different methods used to functionalize naked SPION (brown circles) with PVA (black lines).
Notes: The silica precursor (APTES) grafts the PVA onto naked SPION and provides amino groups and positive charges to obtain a-PVA-grafted-SPION comparable in size, chemistry, and charge to a-PVA-SPION (with adsorbed PVA).
Abbreviations: SPION, superparamagnetic iron oxide nanoparticles; a-PVA, amino-polyvinyl alcohol; PVA, polyvinyl alcohol; AAPTES, (3-aminopropyl)triethoxysilane.
Figure 2Influence of free-floating PVA and a-PVA-grafted-SPION (++) on whole blood cytokine secretion in human immune cells.
Notes: (A) Free-floating PVA. IL1β secretion was analyzed in supernatants collected from human whole blood samples obtained from healthy donors (n=8) after 20 hours incubation with PVA. (B) a-PVA-grafted-SPION (++). Supernatants were collected from whole blood assays [blood samples obtained from healthy donors (n=9)] and analyzed for secreted cytokines. Data are presented as box and whisker plots; whiskers represent minimum to maximum. One-way ANOVA: ***P<0.001; **P<0.01; *P<0.05.
Abbreviations: SPION, superparamagnetic iron oxide nanoparticles; a-PVA, amino-polyvinyl alcohol; ANOVA, analysis of variance; ctrl, control; LPS, lipopolysaccharide; PVA, polyvinyl alcohol; LPS, lipopolysaccharide.
Figure 3Influence of different preparations of NP on the viability and cytokine secretion of human immune cells.
Notes: (A) Whole blood cell survival analysis was performed with blood samples obtained from healthy donors (n=10). Cells were analyzed with Annexin V (an apoptosis marker) and 7AAD (a necrosis marker). (B) Supernatants were collected from whole cell blood survival assays and analyzed for secreted cytokines. Red arrow, cytokines that were significantly increased compared to untreated controls at a SPION concentration of 100 µg/mL; green arrow, cytokines that remained unchanged. One example, IL17 secretion, is presented in detail in (C). Data are presented as box and whisker plots; whiskers represent minimum to maximum. One-way ANOVA: ***P<0.001.
Abbreviations: NP, nanoparticles; SPION, superparamagnetic iron oxide nanoparticles; ANOVA, analysis of variance; a-PVA, amino-polyvinyl alcohol; ctrl, control; LPS, lipopolysaccharide; PVA, polyvinyl alcohol.
Influence of amino PVA-SPION on the concentration of secreted cytokines
| Cytokine (pg/mL) | Ctrl | LPS | PHA-L | G1 1 μg/mL | G1 10 μg/mL | G1 100 μg/mL | G4.1/30 mV 1 μg/mL | G4.1/30 mV 10 μg/mL | G4.1/30 mV 100 μg/mL | G4.1/25 mV 1 μg/mL | G4.1/25 mV 10 μg/mL | G4.1/25 mV 100 μg/mL | Ferumoxsil1 μg/mL | Ferumoxsil 10 μg/mL | Norm serum level |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IL1ra | 19.7 | 403.9 | 304.3 | 23.5 | 127.9 | 205.0 | 17.60 | 24.8 | 233.0 | 20.7 | 11.8 | 42.9 | 34.4 | 11.8 | 133 |
| IL1β | 15.2 | 1,349 | 406.3 | 15.2 | 190.8 | 888.2 | 15.2 | 15.3 | 193.0 | 15.2 | 15.2 | 15.3 | 15.3 | 15.2 | 3 |
| IL2 | nd | 1 | |||||||||||||
| IL4 | nd | 3 | |||||||||||||
| IL5 | nd | 4 | |||||||||||||
| IL6 | 12.5 | 3,172 | 3,172 | 12.3 | 3,125 | 3,172 | 88.2 | 88.3 | 3,172 | 19.5 | 43.89 | 67.3 | 60.2 | 12.5 | 5 |
| IL7 | 21 | ||||||||||||||
| IL8 | 50.6 | 3,099 | 3,109 | 96.5 | 3,109 | 3,124 | 244.0 | 511.5 | 3,109 | 78.4 | 132.8 | 229.9 | 138.5 | 52.4 | 4 |
| IL9 | 13.1 | 99.3 | 110.8 | 13.2 | 87.1 | 106.4 | 13.2 | 21.3 | 96.4 | 21.3 | 13.2 | 31 | 20 | 13.1 | 12 |
| IL10 | 11.9 | 365.9 | 259.7 | 11.9 | 24.3 | 94.2 | 11.9 | 11.9 | 226.1 | 11.9 | 11.9 | 11.9 | 11.9 | 11.9 | 4 |
| IL12 | 17.5 | 18.1 | 17.5 | 17.5 | 17.5 | 17.8 | 17.5 | 17.5 | 17.8 | 17.5 | 17.6 | 17.6 | 17.5 | 17.5 | 16 |
| IL13 | nd | 4 | |||||||||||||
| IL15 | nd | 1 | |||||||||||||
| IL17 | 11 | 72 | 76.6 | 11 | 49.9 | 66.1 | 11.1 | 21.7 | 54.1 | 11.1 | 11.1 | 11.1 | 11.1 | 11 | 21 |
| Eotaxin | 106.8 | 174.6 | 126.3 | 86.1 | 116.1 | 145.5 | 80.3 | 83.7 | 119.5 | 91.4 | 90.4 | 80.6 | 103.7 | 86.2 | 31 |
| FGF basic | 5.3 | 13 | 12.9 | 5.3 | 5.3 | 15.3 | 5.3 | 5.3 | 5.3 | 5.3 | 5.3 | 5.3 | 5.3 | 5.3 | 7 |
| G-CSF | 29.5 | 537.4 | 426 | 41 | 201.0 | 598.2 | 28.3 | 29.9 | 399.8 | 14.4 | 17.9 | 28.3 | 36.6 | 14.4 | 52 |
| GM-CSF | 6.8 | 14.4 | 10.4 | 6.8 | 10.4 | 14 | 6.8 | 6.8 | 10.4 | 6.8 | 6.8 | 6.8 | 6.8 | 6.8 | 6 |
| IFN-γ | 65.1 | 295.6 | 257.6 | 62.9 | 192.8 | 259.7 | 75 | 86.1 | 195.2 | 37 | 72.1 | 71.8 | 78.5 | 66.7 | 77 |
| MCP1 | 64.6 | 1,244 | 1,832 | 210 | 1,868 | 2,194 | 630 | 1,207 | 1,949 | 141.1 | 346.2 | 1,010 | 90.5 | 111.1 | 16 |
| MIP1a | 7.9 | 1,089 | 973.2 | 7.9 | 610.2 | 797.8 | 7.9 | 24.3 | 1,019 | 7.9 | 7.9 | 20.9 | 7.9 | 7.9 | 7 |
| MIP1b | 50.9 | 1,166 | 1,155 | 90.9 | 1,132 | 919.8 | 160.9 | 354.5 | 1,500 | 93.2 | 173.2 | 456.5 | 96.8 | 92.3 | 35 |
| IP10 | 597.3 | 4,536 | 4,931 | 527.1 | 556.1 | 612.6 | 636.8 | 715.0 | 755.8 | 609.7 | 577.8 | 471.3 | 544.6 | 563.8 | 592 |
| PDGF | 255.7 | 504.2 | 618.9 | 280.6 | 419.8 | 626.1 | 283.7 | 182.1 | 119.7 | 246.7 | 181.7 | 107.3 | 280.5 | 186.2 | 1,571 |
| RANTES | 539.3 | 634.4 | 669.7 | 513.8 | 580.4 | 498.2 | 480.3 | 575.2 | 724.3 | 540.7 | 585.5 | 636.1 | 570.6 | 596.5 | 204 |
| TNFα | 40.1 | 2,129 | 1,888 | 61.3 | 811.8 | 1,650 | 70.8 | 68.7 | 1,606 | 40.2 | 40.1 | 62.7 | 62.7 | 40.2 | 35 |
| VEGF | 15.5 | 36.2 | 25.5 | 15.5 | 15.5 | 15.5 | 15.5 | 15.5 | 15.5 | 15.5 | 15.5 | 15.5 | 15.5 | 15.5 | 11 |
Notes: Supernatants were collected from whole blood cell survival assays (blood samples obtained from four healthy donors) after 20 hours with or without SPION treatment and analyzed by multiplex suspension array. Median values are shown for controls (LPS, PHA-L) and the different concentrations of SPION (1–100 µg/mL).
In the right hand column, published normal (norm) serum levels, adapted with permission from John Wiley and Sons, Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S, Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis, Arthritis Rheum, Copyright © 2010 by the American College of Rheumatology,1 or
levels determined using Bio-Plex Pro™ Cytokine Assays, data from Chapman et al.2
Abbreviations: PVA, polyvinyl alcohol; SPION, superparamagnetic iron oxide nanoparticles; ctrl, control; LPS, lipopolysaccharide; norm serum level, normal serum level; nd, not detectable.